These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 24888206)
1. [Dabigatran in prevention of stroke in atrial fibrillation: three years of clinical application]. Zotova IV; Zateĭshchikov DA Kardiologiia; 2014; 54(2):79-85. PubMed ID: 24888206 [No Abstract] [Full Text] [Related]
2. [Differential therapy with the new anticoagulants, 5]. Stiefelhagen P MMW Fortschr Med; 2013 May; 155(9):20. PubMed ID: 23951642 [No Abstract] [Full Text] [Related]
3. [Advantages of NOAKs validated in clinical routine]. Ameri AA MMW Fortschr Med; 2015 May; 157(9):70. PubMed ID: 26012835 [No Abstract] [Full Text] [Related]
4. Dabigatran for stroke prevention in nonvalvular atrial fibrillation: focus in the geriatric population. Brunetti L; Chen C; White J Consult Pharm; 2014 Mar; 29(3):169-78. PubMed ID: 24589766 [TBL] [Abstract][Full Text] [Related]
5. Dabigatran for the prevention of stroke in atrial fibrillation: is RE-LY reliable? Marín F; Roldán V; Lip GY Expert Opin Pharmacother; 2012 Jun; 13(8):1087-90. PubMed ID: 22568622 [No Abstract] [Full Text] [Related]
6. Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin. Zalesak M; Siu K; Francis K; Yu C; Alvrtsyan H; Rao Y; Walker D; Sander S; Miyasato G; Matchar D; Sanchez H Circ Cardiovasc Qual Outcomes; 2013 Sep; 6(5):567-74. PubMed ID: 23922182 [TBL] [Abstract][Full Text] [Related]
7. [Prophylaxis of stroke and embolisms in atrial fibrillation--what is new in the guidelines?]. Lewalter T MMW Fortschr Med; 2012 Mar; 154(5):50-2, 54. PubMed ID: 22624265 [No Abstract] [Full Text] [Related]
8. Benefits of dabigatran maintained for more than two years. Aalbers J Cardiovasc J Afr; 2012 Nov; 23(10):576. PubMed ID: 23192264 [No Abstract] [Full Text] [Related]
9. Australian MPs demand more data on dabigatran for atrial fibrillation. Brill D BMJ; 2013 Jan; 346():f303. PubMed ID: 23321733 [No Abstract] [Full Text] [Related]
10. Risk of major bleeding and the standard doses of dabigatran. Antoniazzi S; Berdaï D; Conti V; Clementi E; Salvo F Eur J Intern Med; 2014 Jul; 25(6):e73-5. PubMed ID: 24629895 [No Abstract] [Full Text] [Related]
11. Dabigatran for stroke prevention in all patients with atrial fibrillation? Hunchuck JE; Lake JD Pharmacotherapy; 2011 Aug; 31(8):725-8. PubMed ID: 21923597 [No Abstract] [Full Text] [Related]
12. Dabigatran efficacy-safety assessment for stroke prevention in patients with atrial fibrillation. Eikelboom JW; Quinlan DJ; Connolly SJ; Hart RG; Yusuf S J Thromb Haemost; 2012 May; 10(5):966-8. PubMed ID: 22360879 [No Abstract] [Full Text] [Related]
13. Modeling of the impact on health outcomes of the use of dabigatran in patients with atrial fibrillation. Chevalier J; Giroud M; de Pouvourville G Cerebrovasc Dis; 2013; 35(4):320-6. PubMed ID: 23615428 [TBL] [Abstract][Full Text] [Related]
16. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. Mantha S; Ansell J Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145 [TBL] [Abstract][Full Text] [Related]
17. Benefit-risk assessment of dabigatran in the treatment of stroke prevention in non-valvular atrial fibrillation. Meyer Dos Santos S; Harder S Drug Saf; 2014 May; 37(5):295-307. PubMed ID: 24683059 [TBL] [Abstract][Full Text] [Related]
18. Public health. Change of heart. Taylor J Health Serv J; 2012 Jul; 122(6315):19-20. PubMed ID: 23155563 [No Abstract] [Full Text] [Related]